<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04950907</url>
  </required_header>
  <id_info>
    <org_study_id>20210301</org_study_id>
    <nct_id>NCT04950907</nct_id>
  </id_info>
  <brief_title>Uniportal Tubeless VATS for the Evaluation of Biopsy for Second-generation Sequencing in Patients With Advanced NSCLC</brief_title>
  <official_title>A Randomized Controlled Study of Single Port Tubeless VATS for the Evaluation of Qualified Rate of Biopsy for Second-generation Tibial Specimens in Patients With Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jianxing He</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-center, prospective, open-label randomized controlled study. This study&#xD;
      evaluates the eligibility rate of different biopsy methods (tubeless tubeless VATS vs. CT&#xD;
      guided fine needle aspiration) for the detection of molecular genetic characteristics of&#xD;
      peripheral NSCLC next-generation sequencing, and its main purpose is to evaluate the use of&#xD;
      tumor gene profiling (NGS) The best biopsy technique, the First Affiliated Hospital of&#xD;
      Guangzhou Medical University is the research center. It is expected to be completed between&#xD;
      2021-3-1 and 2023-3-1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 15, 2021</start_date>
  <completion_date type="Anticipated">June 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 26, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualified Rate of Biopsy for Second-generation Tibial Specimens</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Different biopsy methods (single-port tubeless VATS biopsy vs CT-guided fine-needle aspiration biopsy) are used to evaluate the qualification rate of samples obtained for NGS testing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Progression Free Survival of patients under different biopsy methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Overall Survival of patients under different biopsy methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Content Size</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Tumor Content of patients under different biopsy methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene Mutation Rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Gene Mutation Rate of patients under different biopsy methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug sensitive mutation detection rate</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Drug sensitive mutation detection rate of patients under different biopsy methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of PD-L1 expression</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Detection of PD-L1 expression of patients under different biopsy methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TMB detection situation</measure>
    <time_frame>up to 2 years</time_frame>
    <description>TMB detection situation of patients under different biopsy methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between tumor cell content and detection rate of sensitive mutations</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complications</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative patient experience score</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Usage rate of targeted drug</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success rate of enrollment</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative MRD detection</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>NSCLC</condition>
  <condition>Biopsy Technique</condition>
  <condition>VATS</condition>
  <condition>CT Guided Puncture Biopsy</condition>
  <condition>NGS</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uniportal VATS biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CT-guided fine needle biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>vats</intervention_name>
    <description>Use uniportal tubeless VATS to obtain the biopsy</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CT-guided fine needle biopsy</intervention_name>
    <description>Use CT-guided fine needle to obtain the biopsy</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent is obtained&#xD;
&#xD;
          -  Assessed by more than 2 surgeons, patients whose lesions can be achieved by tubeless&#xD;
             single-port thoracoscopic surgical biopsy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of other malignant tumors.&#xD;
&#xD;
          -  The general condition is not suitable for puncture, bronchoscopy, or surgery (such as&#xD;
             cardiopulmonary dysfunction, high risk of bleeding, allergy to anesthetics, confusion,&#xD;
             inability to exercise, etc.)&#xD;
&#xD;
          -  History of lung surgery, tuberculosis and coal mine work experience, etc. may cause&#xD;
             severe chest adhesions; other situations that conflict with the biopsy process&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 14, 2021</study_first_submitted>
  <study_first_submitted_qc>June 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>July 10, 2021</last_update_submitted>
  <last_update_submitted_qc>July 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Guangzhou Medical University</investigator_affiliation>
    <investigator_full_name>Jianxing He</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>biopsy technique</keyword>
  <keyword>VATS</keyword>
  <keyword>CT guided puncture biopsy</keyword>
  <keyword>NGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

